Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer

Annals of Oncology

Volumn 9, Issue 12, 1998, Pages 1323-1330

  Mross, K ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cemadotin HCl; Dolastatin 15 analog; Phase I study

Indexed keywords

ANTIMITOTIC AGENT; CEMADOTIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MAXIMUM PERMISSIBLE DOSE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL DISEASES; GROWTH INHIBITORS; HUMANS; HYPERTENSION; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MITOSIS; MYOCARDIAL ISCHEMIA; NEOPLASMS; NEUTROPENIA; OLIGOPEPTIDES; PAIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032413095     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008430515881     Document Type: Article

References (30)

1. Pettit GR, Kamano Y, Fujii Y et al. Marine animal biosynthetic constituents for cancer chemotherapy. J Natl Prod 1981; 44: 482-5.
2. Pettit GR, Kamano Y, Herald CL et al. The isolation and structure of a remarkable marine antineoplastic constituent: Dolastatin 10. J Am Chem Soc 1987; 109: 6883-5.
3. Pettit GR, Kamano Y, Dufresne C et al. Isolation and structure of the cytostatic linear depsipeptide Dolastatin 15. J Org Chem 1989; 54: 6005-6.
4. Quentmeier H, Brauner S, Petitt GR, Drexler HG. Cytostatic effects of Dolastatin 10 and Dolastatin 15 on human leukemia cell lines. Leuk Lymph 1992; 6: 245-50.
5. Hu ZB, Gignac SM, Quentmeier H et al. Effects of dolastatins on human B-lymphocytic leukemia cell lines. Leuk Res 1993; 4: 333-9.
6. Beckwith M, Urba WJ, Longo DL. Growth inhibition of human lymphoma cell lines by the marine products, Dolastatins 10 and 15. J Natl Cancer Inst 1993; 84: 483-8.
7. Villalona-Calero M, Degen D, Barlozzari T, von Hoff D. LU103793: Evaluation by human tumor clonogenic assay of a novel dolastatin. Proc AACR 1995; 36: 394a.
8. Smith P, Nelson C, Janssen B et al. Pre-clinical anti-tumor activity of a novel water-soluble Dolastatin 15 analog (LU103793). Proc AACR 1995; 36: 393a.
9. Smith P, Nelson C, Spigelman M et al. In vivo anti-tumor activity of LU103793: Evidence for schedule dependency in MX-1. KB3-1 and P388 tumor models. Proc AACR 1995; 36: 394a.
10. Nelson C, Cocchiaro C, Smith P et al. Prcclinical pharmacology of LU103793, synthetic derivative of dolastatin 15. Proceedings of the 9th NCI-EORTC symposium on new drugs in cancer therapy 1996 (Abstr 114).
11. De Arruda M, Cocchiaro C, Nelson C et al. LU103793 (NSC D-669356): A synthetic peptide that interacts with microtubules and inhibits mitosis. Cancer Res 1995; 55: 3085-92.
12. Maki A, Diwakaran H, Redman B. The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large-cell lymphomas. Anticancer Drugs 1995; 6: 392-7.
13. Cocchiaro C, Nelson C, Haupt A et al. Induction of apoptosis in vitro and in rivo by treatment with LU103793. Proc AACR 1996; 37: 398a.
14. Hergenroder S. Effect of amlodipine, trandolapril, nifedipine, clonidine, dihydralazine and prasozin on LU103793 induced changes of cardiovascular parameters after single intravenous administration in anaesthesised dogs. Investigator Brochure, In House Report - Knoll AG MPF/HPK 941.
15. Hege HG.Weymann J. Studies on the metabolism ofLU103793 in the dog after single i.v. dosing. Metabolite pattern and structure elucidation of the major metabolites. Investigator Broschure, In House Report - Knoll AG MPF/EB 9411.
16. Barlozzari T. Personal communication.
17. Blaich G, Halm S, Heimann W. LU103793 - single dose toxicity study after intravenous administration in the mouse and in the rat. Investigator Broschure, In House Report - Knoll AG MPF/ ET 9355,9356.
18. Fischer A, Heimann W, Jochims K, Neidhardt R. LU103793 repeated dose toxicity study (3 treatment cycles) after intravenous administration in beagle dogs. Investigator Broschure, In House Report - Knoll AG MPF/ET9354.
19. Mross K, Herbst K, Berdel W et al. Phase I study with the cytostatic peptide LUI03793 administered as i.v. bolus injection. Ann Oncol 1996; 7 (Suppl 1): 100.
20. Mross K, Herbst K, Berdel WE et al. Phase I clinical and pharmacokinetic study of LU103793 (Cemadotin Hydrochloride) as an intravenous bolus injection in patients with metastatic solid tumors. Onkologie 1996; 19: 490-5.
21. Gibaldi M. Biopharmaceutics and Clinical Pharmacokinetics. Philadelphia: Lea and Febiger 1991.
22. Heinzel G, Wolozczak R, Thomann P. Pharmacokinetic and Pharmacodynamic Data System for the PC. Stuttgart: Fischer 1993.
23. Christian MC, Pluda JM, Ho PTC et al. Promising new agents under development by the division of cancer treatment, diagnosis, and centers of the National Cancer Institute. Semin Oncol 1997; 24:219-40.
24. Wolff I, Brunsch U, Cavalli F et al. Phase I clinical + pharmacokinetic study of the dolastatin analogue LU103793 on a weekly x 4 schedule. Ann Oncol 1996; 7 (Suppl 5): 124.
25. Villalona-Calero M, Jakimowicz K, Razvillas B et al. LUI03793: A phase I study of a novel dolastatin. Ann Oncol 1996; 7 (Suppl 1): 100.
26. Newman RA, Fuentes A, Covey JM. Preclinical pharmacology of the natural marine product Dolastatin 10 (NSC 376128). Drug Metab Dispo 1994; 22: 428-32.
27. Mross K, Fiebig HH, Berdel Wet al. Clinical and pharmacokinetic phase I study with LUI03793 administered as 24-hour infusion. Proc ASCO 1996; 15: 482a.
28. Wolff I, Brunsch U, Cavalli F et al. Phase I clinical study of LUI03793 (cemadotin) given on a weekly (wkly) x 4 schedule. Proc ASCO 1997; 16: 223a.
29. Villalona-Calero M, von Hoff D, Eckhardt G et al. Phase I and pharmakokinetic (PK) study of LU103793, a water soluble analog of Dolastin 15, on a daily x 5 schedule. Proc ASCO 1997; 16: 223a.
30. McElroy EA, Pilot HC, Erlichman C et al. Phase I trial of Dolastatin-10 in patients with advanced solid tumors. Proc ASCO 1997; 16: 223a.